Table 1.
Main phase II studies with HER2-targeted therapies in refractory HER2-positive mCRC.
| Reference | Nr. of Patients | HER2 Overexpression (%) | Treatment | ORR (%) | mPFS | mOS |
|---|---|---|---|---|---|---|
| HERACLES-A | 32 | 22 (2+); 78 (3+) | trastuzumab + lapatinib | 28 | 4.7 | 10 |
| HERACLES-B | 31 | 20 (2+); 80 (3+) | pertuzumab + TDM-1 | 9.7 | 4.1 | - |
| MyPathway | 57 | 100 | trastuzumab + pertuzumab | 32 | 2.9 | 11.5 |
| TRIUMPH | 18 | 100 | trastuzumab + pertuzumab | 35 | 4 | - |
| TAPUR | 28 | 100 | trastuzumab + pertuzumab | 14 | 3.8 | - |
| DESTINY-CRC01 | 78 | A: 68 (3+/2+ IHC+); B: 9 (2+ IHC−); C: 23 (1+) | trastuzumab deruxtecan | A: 45.3; B/C: − | 6.3 - |
15.5 - |
| MOUNTAINEER (recruiting) | 26 | 100 | trastuzumab + tucatinib | 52.2 | 8.1 | 18.7 |
| HER2-FUSCC-G (recruiting) |
11 | 100 | Trastuzumab + pirotinib | 45.5 | 7.8 | 14.9 |
Legend: IHC: immunohistochemistry; mOS: median overall survival; mPFS: median progression-free survival; Nr.: number; ORR: overall response rate.